Key Takeaways
- Naltrexone addresses the neurobiological dimension of addiction, while behavioral therapies address the psychological, behavioral, and social dimensions — together they produce outcomes neither achieves alone.
- The COMBINE trial demonstrated that naltrexone plus behavioral therapy outperformed either treatment alone for alcohol use disorder, with the combination producing the highest rates of abstinence and reduced drinking.
- Cognitive behavioral therapy (CBT) has the strongest evidence base for pairing with naltrexone, targeting the thought patterns and behavioral cues that trigger craving and substance use.
- Motivational interviewing (MI) enhances treatment engagement, medication adherence, and willingness to participate in behavioral programming — particularly valuable in the early stages of naltrexone treatment.
- Peer support and recovery coaching extend the benefits of naltrexone and therapy into everyday life, providing community accountability and lived-experience guidance that clinicians alone cannot offer.
- Treating co-occurring mental health disorders is essential — unaddressed depression, anxiety, PTSD, and trauma are the most common drivers of relapse in patients on naltrexone.
Why Naltrexone Alone Is Insufficient: The Limits of Medication
Addiction is a complex, multi-dimensional disorder that involves neurobiological dysregulation, learned behavioral patterns, psychological distress, trauma histories, disrupted social systems, and environmental triggers. Naltrexone — regardless of formulation — addresses one dimension of this complexity: it pharmacologically reduces the rewarding properties of opioids and alcohol, dampening the neurochemical reinforcement that sustains compulsive use. This is a meaningful and evidence-based intervention. However, it leaves the other dimensions entirely unaddressed. A patient on Vivitrol who has never developed alternative coping strategies, who returns to the same social environment that enabled their use, and who has unresolved trauma driving emotional dysregulation is at high relapse risk the moment their naltrexone protection wanes.
The research literature is unambiguous on this point. A systematic review published in JAMA Psychiatry analyzing 34 randomized controlled trials found that combined pharmacotherapy and behavioral therapy consistently produced superior outcomes to either treatment modality alone across multiple substance use disorders. For OUD specifically, SAMHSA's Treatment Improvement Protocol (TIP) 63 states explicitly that "medication alone is rarely sufficient for recovery from opioid use disorder" and mandates integration of counseling services as a standard of care component. ASAM's clinical practice guidelines similarly identify concurrent psychosocial treatment as a core element of any MAT program.
At Trust SoCal in Fountain Valley, every patient on naltrexone — whether oral or injectable — is enrolled in concurrent behavioral programming. Our Orange County treatment model integrates medication management with individual therapy, group counseling, trauma-informed care, and community support in a seamless, coordinated program. To learn how our integrated naltrexone plus therapy approach works, call (949) 280-8360.
Medication changes the brain's chemistry. Therapy changes the patient's relationship with themselves, their history, and their world. Recovery requires both.
What Behavioral Therapy Addresses That Naltrexone Cannot
Understanding the specific functions of behavioral therapy in MAT helps patients and families appreciate why the combination is not merely additive but synergistic.
- Identifying and restructuring cognitive distortions and triggering thought patterns that precede substance use.
- Building practical coping skills for managing stress, emotional pain, and environmental cues without substances.
- Processing underlying trauma, grief, or adverse childhood experiences that drive self-medication.
- Repairing and rebuilding relationships damaged by substance use through family and couples therapy.
- Developing a meaningful, values-aligned life in recovery that provides intrinsic motivation to maintain sobriety.
Cognitive Behavioral Therapy: The Evidence-Based Core
Cognitive behavioral therapy (CBT) is the most extensively researched behavioral therapy for substance use disorders and carries the strongest evidence base for integration with naltrexone. Developed originally by Aaron Beck for depression and adapted for addiction by G. Alan Marlatt and other pioneers, CBT for SUD operates on the premise that substance use is maintained by identifiable thought patterns and behavioral chains that can be systematically identified, challenged, and replaced with healthier alternatives. CBT teaches patients to recognize high-risk situations and emotional states that trigger cravings, identify the automatic thoughts that fuel urges to use, challenge and restructure those thoughts, and deploy evidence-based coping strategies in real time.
In the context of naltrexone treatment, CBT serves as both a maintenance strategy and a relapse prevention protocol. Naltrexone reduces the neurochemical reward of substance use, while CBT simultaneously attacks the psychological infrastructure that drives drug-seeking behavior. Several randomized controlled trials have demonstrated that patients receiving both naltrexone and CBT show significantly better 12-month outcomes than those receiving either treatment alone, with the combination producing roughly 30 to 40 percent higher rates of sustained abstinence or significant reduction in use. This synergy has been replicated across OUD, AUD, and co-occurring disorder populations.
CBT delivery in the context of naltrexone treatment can take multiple forms: individual therapy sessions (typically weekly, 45 to 60 minutes), structured group CBT programs (2 to 3 times per week in IOP settings), self-guided digital CBT modules delivered via app or web platform, and skills-based workbooks. Trust SoCal's Orange County programs deliver CBT through licensed therapists trained in addiction-specific CBT protocols, with flexible scheduling options to accommodate patients' employment and family responsibilities. To discuss CBT availability within our naltrexone treatment programs, contact (949) 280-8360.
CBT skills are most effective when practiced between therapy sessions. Ask your therapist to assign specific homework exercises — such as thought records, behavioral experiments, or urge-surfing logs — to build competency in real-world application, not just in-session discussion.
Core CBT Skills Taught in Naltrexone-Integrated Treatment
The following CBT skill domains form the core curriculum in most naltrexone-integrated treatment programs, with each skill directly counteracting a specific vulnerability to relapse.
- Functional analysis: mapping the antecedents, behaviors, and consequences of substance use to identify personalized trigger chains.
- Urge surfing: observing cravings as time-limited waves rather than commands to use, using mindfulness-based techniques to ride them out without acting.
- Cognitive restructuring: identifying and challenging permission-giving thoughts and catastrophic thoughts that fuel emotional relapse.
- Problem-solving skills: developing structured approaches to life stressors that previously triggered substance use.
- Relapse rehearsal: role-playing high-risk scenarios and practicing evidence-based refusal and coping responses before they occur in real life.
Motivational Interviewing and Peer Support in Naltrexone Programs
Motivational interviewing (MI) is a collaborative, person-centered counseling style designed to resolve ambivalence about change and strengthen intrinsic motivation for recovery. Developed by William Miller and Stephen Rollnick, MI is grounded in the understanding that most people with SUD experience significant ambivalence — part of them wants to stop using, and part of them is not yet ready or willing. MI helps clinicians explore this ambivalence non-judgmentally, elicit the patient's own reasons for change, and build commitment to specific action steps such as medication adherence, therapy attendance, and trigger avoidance.
In the naltrexone context, MI is particularly valuable in two specific phases: pre-treatment, to help ambivalent patients commit to the detoxification and initiation process, and during maintenance, to address medication non-adherence, engagement lapses, and emerging ambivalence about continuing treatment. Research shows that a single MI session before initiating naltrexone significantly increases the probability of completing detoxification, presenting for the first injection appointment, and maintaining medication adherence at 3-month follow-up. MI is brief, practical, and can be delivered in primary care, specialty addiction treatment, or even peer settings.
Peer support — the provision of guidance, accountability, and social connection by individuals with lived recovery experience — is an increasingly evidence-supported complement to both naltrexone therapy and professional behavioral treatment. Recovery coaches, peer specialists, and community recovery programs such as Narcotics Anonymous and SMART Recovery provide something that clinicians cannot: authentic shared experience, 24/7 availability, and community belonging. Studies consistently show that peer support engagement is associated with improved MAT adherence, higher rates of sustained sobriety, and better quality of life outcomes. Trust SoCal connects patients with Orange County peer support networks, recovery coaches, and alumni communities as part of standard aftercare planning.
Both NA and AA have issued statements clarifying that members on prescribed MAT medications including naltrexone are welcome and that the decision to take prescribed medications is a personal medical matter between the patient and their physician. Patients should not feel pressured by group members to discontinue prescribed naltrexone.
Recovery Support Services That Complement Naltrexone
Beyond professional therapy, a range of community-based recovery support services amplify naltrexone's benefits and provide the social scaffolding that sustains long-term recovery.
- Narcotics Anonymous (NA) and Alcoholics Anonymous (AA): free, widely available peer support with naltrexone-compatible 12-step frameworks.
- SMART Recovery: science-based, non-12-step peer support that explicitly welcomes MAT participants including those on naltrexone.
- Recovery coaching: paid or volunteer peer support with personalized guidance on navigating recovery challenges.
- Sober living houses: structured, drug-free housing environments that reduce relapse risk during early recovery.
- Vocational rehabilitation and employment support: addressing financial instability and unemployment, which are major relapse risk factors.
Co-Occurring Disorders: The Essential Missing Piece
The most commonly overlooked element in naltrexone treatment programs is the identification and integrated treatment of co-occurring mental health disorders. Population studies consistently report that approximately 50 to 60 percent of individuals with OUD or AUD meet diagnostic criteria for at least one co-occurring psychiatric condition, including major depressive disorder, generalized anxiety disorder, PTSD, bipolar disorder, ADHD, or borderline personality disorder. These conditions are not incidental to substance use disorders — they are frequently the psychological engine that drives self-medication with substances and sustains the cycle of addiction despite negative consequences.
Unaddressed co-occurring disorders are the single largest predictor of naltrexone treatment failure and early relapse. A patient with undertreated PTSD who is placed on Vivitrol and enrolled in generic addiction counseling will likely relapse when their trauma symptoms — nightmares, hypervigilance, emotional flashbacks — overwhelm their coping capacity, regardless of the pharmacological opioid blockade naltrexone provides. Effective treatment requires accurate psychiatric assessment at intake, diagnosis of all present conditions, and concurrent, coordinated treatment of both the substance use disorder and the co-occurring condition(s) in what is called integrated dual-diagnosis treatment.
Trust SoCal's Orange County programs include comprehensive psychiatric evaluation as part of the intake process, with access to psychiatrists who can prescribe evidence-based medications for co-occurring conditions alongside naltrexone. Our integrated dual-diagnosis treatment model ensures that patients receive simultaneous, coordinated care for all active diagnoses, not sequential treatment that delays addressing co-occurring conditions until "after" addiction treatment. To discuss dual-diagnosis evaluation and integrated treatment options, call (949) 280-8360.
Benzodiazepines prescribed for co-occurring anxiety disorders create a significant safety risk in OUD patients on naltrexone, as they can substitute for opioids in the misuse continuum and increase central nervous system depression risk. Non-benzodiazepine anxiolytics should always be considered first-line for anxiety in this population, with benzos reserved for acute, time-limited indications under close monitoring.
Most Common Co-Occurring Disorders in Naltrexone Patients
The following psychiatric conditions are most frequently identified in OUD and AUD patients receiving naltrexone and require integrated treatment planning to prevent naltrexone failure.
- Major Depressive Disorder (MDD): present in 30 to 40% of AUD patients; antidepressants (SSRIs) are first-line and compatible with naltrexone.
- PTSD: present in 30 to 50% of OUD patients; trauma-focused CBT (TF-CBT, EMDR) paired with naltrexone significantly improves outcomes.
- Generalized Anxiety Disorder: common in AUD; non-benzodiazepine anxiolytics (buspirone, SSRIs, SNRIs) appropriate with naltrexone.
- ADHD: untreated ADHD dramatically increases relapse risk; non-stimulant options (atomoxetine, bupropion) or monitored stimulants are compatible with naltrexone.
- Bipolar Disorder: mood stabilization with lithium or atypical antipsychotics required before and during naltrexone treatment for OUD or AUD.
Trust SoCal Editorial Team, Clinical Review Board
Editorial & Clinical Review
